Cosmo Godino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cosmo Godino has a total of 795 co-authors. Here are the top co-authors by number of shared publications:
Antonio Colombo
IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
119 shared publicationsMatteo Montorfano
Interventional Cardiovascular Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
60 shared publicationsAlberto Margonato
Cardiology Unit, Heart Valve Center, IRCCS Ospedale San Raffaele, Milan, Italy (C.G., A. Margonato)
58 shared publications- Azeem Latib
Montefiore Medical Center
57 shared publications - Alaide Chieffo
Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
50 shared publications Mauro Carlino
Cardio‐Thoracic‐Vascular Department San Raffaele Scientific Institute Milan Italy
39 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (11) , 532
Hemoglobin-to-RDW Ratio and All-Cause Mortality in Idiopathic Pulmonary Fibrosis: Complementary Value to Echocardiographic Right Ventricular–Pulmonary Arterial Coupling
Background: The hemoglobin-to-red cell distribution width ratio (HRR) is a composite hematologic biomarker that integrates oxygen-carrying capacity and inflammation-related erythrocyte variability. Its prognostic value in idiopathic pulmonary fibrosis (IPF), and its relationship with right ventricular (RV) function, have not been established. Methods: We conducted a single-center retrospective study of 198 patients with IPF. A total of 165 patients with baseline hemoglobin, red cell distribution width (RDW) and date of diagnosis available constituted the analytical cohort. An HRR cutoff (≤0.86) was derived by time-dependent Receiver Operating Characteristic (ROC) curve analysis at 5 years. All-cause mortality from diagnosis was assessed by Kaplan–Meier and Cox regression, with bootstrap internal validation. Associations between hematologic markers and TAPSE (Tricuspid Annular Plane Systolic Excursion), PAPs (pulmonary arterial systolic pressure) and TAPSE/PASP were examined by linear and logistic regression, followed by joint stratification of HRR and RV–PA coupling. Results: Over a median follow-up of 70.3 months, 57 patients (34.5%) died. Low HRR was associated with higher mortality (72.7% vs. 15.5%; adjusted HR 3.07, 95% CI 1.68–5.63; optimism-corrected HR 2.37) and improved a clinical model beyond RDW (likelihood-ratio p = 0.012). HRR was not associated with TAPSE, PAPs, TAPSE/PASP or RV–PA uncoupling. In exploratory joint stratification, mortality rose from 11.7% with both markers preserved to 100% with both abnormal (age-adjusted HR 6.47, 95% CI 2.64–15.86). At 5 years, HRR and RDW showed similar discrimination (time-dependent AUC 0.70 and 0.71), higher than TAPSE/PASP (0.61). Conclusions: HRR is a simple, inexpensive and independent predictor of mortality in IPF that is unrelated to RV–PA coupling. The two markers provide complementary prognostic information, and their combination identifies a subgroup at very high risk. These findings require external validation.
- 23 October 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (11) , 532
Open AccessHemoglobin-to-RDW Ratio and All-Cause Mortality in Idiopathic Pulmonary Fibrosis: Complementary Value to Echocardiographic Right Ventricular–Pulmonary Arterial Coupling
Background: The hemoglobin-to-red cell distribution width ratio (HRR) is a composite hematologic biomarker that integrates oxygen-carrying capacity and inflammation-related erythrocyte variability. Its prognostic value in idiopathic pulmonary fibrosis (IPF), and its relationship with right ventricular (RV) function, have not been established. Methods: We conducted a single-center retrospective study of 198 patients with IPF. A total of 165 patients with baseline hemoglobin, red cell distribution width (RDW) and date of diagnosis available constituted the analytical cohort. An HRR cutoff (≤0.86) was derived by time-dependent Receiver Operating Characteristic (ROC) curve analysis at 5 years. All-cause mortality from diagnosis was assessed by Kaplan–Meier and Cox regression, with bootstrap internal validation. Associations between hematologic markers and TAPSE (Tricuspid Annular Plane Systolic Excursion), PAPs (pulmonary arterial systolic pressure) and TAPSE/PASP were examined by linear and logistic regression, followed by joint stratification of HRR and RV–PA coupling. Results: Over a median follow-up of 70.3 months, 57 patients (34.5%) died. Low HRR was associated with higher mortality (72.7% vs. 15.5%; adjusted HR 3.07, 95% CI 1.68–5.63; optimism-corrected HR 2.37) and improved a clinical model beyond RDW (likelihood-ratio p = 0.012). HRR was not associated with TAPSE, PAPs, TAPSE/PASP or RV–PA uncoupling. In exploratory joint stratification, mortality rose from 11.7% with both markers preserved to 100% with both abnormal (age-adjusted HR 6.47, 95% CI 2.64–15.86). At 5 years, HRR and RDW showed similar discrimination (time-dependent AUC 0.70 and 0.71), higher than TAPSE/PASP (0.61). Conclusions: HRR is a simple, inexpensive and independent predictor of mortality in IPF that is unrelated to RV–PA coupling. The two markers provide complementary prognostic information, and their combination identifies a subgroup at very high risk. These findings require external validation.
- Open Access
- 5 August 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (8)
Mitral Regurgitation in Contemporary Practice: From Diagnosis to Management
Mitral regurgitation (MR) is the most prevalent valvular heart disease in developed countries, affecting approximately 1 in 50 individuals in the general population and about 1 in 10 individuals older than 75 years. Despite its frequency, MR remains a complex clinical challenge due to its heterogeneous etiology, variable natural history, and evolving therapeutic landscape. The 2025 ESC/EACTS guidelines have introduced a paradigm shift, transitioning from a purely morphological classification to a mechanism-based framework that distinguishes primary, ventricular secondary, and atrial secondary MR. This review provides a comprehensive overview of contemporary MR management. We discuss the updated classification system and the associated implications for risk stratification, emphasizing how the underlying mechanism of MR influences prognosis and guides treatment selection. The diagnostics section addresses multimodality imaging strategies, detailing the complementary roles of echocardiography, cardiac magnetic resonance (CMR), and cardiac computed tomography (CCT) in assessing severity, characterizing anatomy, and planning interventions. The management section addresses optimization of medical therapy, surgical techniques (repair versus replacement, including conventional and minimally invasive approaches), and transcatheter interventions, with particular focus on mitral transcatheter edge-to-edge repair (M-TEER) and emerging transcatheter mitral valve replacement technologies. We propose an integrated, stepwise management algorithm that incorporates early risk markers, including natriuretic peptides, to guide the timing of intervention before irreversible myocardial damage occurs. The critical role of multidisciplinary heart valve teams (HVTs) in individualizing treatment decisions is highlighted throughout. Early recognition of MR and timely intervention are paramount to prevent progression to irreversible left ventricular dysfunction and heart failure. The mechanism-based classification enables more precise patient phenotyping and treatment tailoring. Transcatheter therapies have expanded therapeutic options for high-risk surgical patients, although careful patient selection remains essential. Natriuretic peptides have emerged as valuable biomarkers for identifying candidates who may benefit from earlier intervention. Contemporary MR management requires the integration of advanced imaging, mechanism-based classification, and collaborative decision-making within HVTs. As therapeutic options continue to expand, optimal outcomes depend on matching the right intervention to the right patient at the right time.
- 5 August 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (8)
Open AccessMitral Regurgitation in Contemporary Practice: From Diagnosis to Management
Mitral regurgitation (MR) is the most prevalent valvular heart disease in developed countries, affecting approximately 1 in 50 individuals in the general population and about 1 in 10 individuals older than 75 years. Despite its frequency, MR remains a complex clinical challenge due to its heterogeneous etiology, variable natural history, and evolving therapeutic landscape. The 2025 ESC/EACTS guidelines have introduced a paradigm shift, transitioning from a purely morphological classification to a mechanism-based framework that distinguishes primary, ventricular secondary, and atrial secondary MR. This review provides a comprehensive overview of contemporary MR management. We discuss the updated classification system and the associated implications for risk stratification, emphasizing how the underlying mechanism of MR influences prognosis and guides treatment selection. The diagnostics section addresses multimodality imaging strategies, detailing the complementary roles of echocardiography, cardiac magnetic resonance (CMR), and cardiac computed tomography (CCT) in assessing severity, characterizing anatomy, and planning interventions. The management section addresses optimization of medical therapy, surgical techniques (repair versus replacement, including conventional and minimally invasive approaches), and transcatheter interventions, with particular focus on mitral transcatheter edge-to-edge repair (M-TEER) and emerging transcatheter mitral valve replacement technologies. We propose an integrated, stepwise management algorithm that incorporates early risk markers, including natriuretic peptides, to guide the timing of intervention before irreversible myocardial damage occurs. The critical role of multidisciplinary heart valve teams (HVTs) in individualizing treatment decisions is highlighted throughout. Early recognition of MR and timely intervention are paramount to prevent progression to irreversible left ventricular dysfunction and heart failure. The mechanism-based classification enables more precise patient phenotyping and treatment tailoring. Transcatheter therapies have expanded therapeutic options for high-risk surgical patients, although careful patient selection remains essential. Natriuretic peptides have emerged as valuable biomarkers for identifying candidates who may benefit from earlier intervention. Contemporary MR management requires the integration of advanced imaging, mechanism-based classification, and collaborative decision-making within HVTs. As therapeutic options continue to expand, optimal outcomes depend on matching the right intervention to the right patient at the right time.
- 25 June 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (7) , e019717
Prognostic Implications of RV-Arterial Coupling Estimated by CMR in a Large Cohort of Tricuspid Regurgitation Patients
BACKGROUND: Right ventricular-pulmonary arterial coupling is a known prognostic marker in patients with tricuspid regurgitation (TR). However, its assessment by cardiac magnetic resonance and its clinical implications have not been evaluated. We aimed to assess the prognostic role of a cardiac magnetic resonance surrogate of right ventricular-pulmonary arterial coupling in a large cohort of patients with a spectrum of TR severity. METHODS: Comprehensive data were collected from patients referred for cardiac magnetic resonance from 2019 to 2024 who had TR quantification. Right ventricular-pulmonary arterial coupling was calculated by dividing the forward right ventricular stroke volume (f-RVSV) by the right ventricular end-systolic volume (ESV). The outcome of interest was the composite of all-cause death and heart failure hospitalization, under medical management. RESULTS: In the 631 patients included, median age was 66 (interquartile range [IQR], 54–75) years, median tricuspid regurgitant volume was 18 (IQR, 12–30 mL), median left ventricular ejection fraction was 53 (IQR, 41–61)%, median RV ejection fraction was 53 (IQR, 45–58)%, and median f-RVSV/ESV ratio was 0.82 (IQR, 0.58–1.11). In restricted spline curve analysis, the f-RVSV/ESV ratio cutoff associated with a hazard >1 for the composite outcome was ≤0.57. At baseline, a low f-RVSV/ESV ratio was strongly associated with subjective and objective signs of right heart failure, higher TRI-SCORE, and worse right-sided chamber remodeling (all P P P =0.004). Finally, patients with low f-RVSV/ESV displayed a worse long-term prognosis across mild, moderate, and severe TR groups ( P P P =0.018, respectively). CONCLUSIONS: In this large cohort of patients with a wide spectrum of TR severity, right ventricular-pulmonary arterial coupling assessed by cardiac magnetic resonance was strongly associated with right-sided heart failure and worse long-term prognosis, even after comprehensive adjustment.
- 25 June 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (7) , e019717
Prognostic Implications of RV-Arterial Coupling Estimated by CMR in a Large Cohort of Tricuspid Regurgitation Patients
BACKGROUND: Right ventricular-pulmonary arterial coupling is a known prognostic marker in patients with tricuspid regurgitation (TR). However, its assessment by cardiac magnetic resonance and its clinical implications have not been evaluated. We aimed to assess the prognostic role of a cardiac magnetic resonance surrogate of right ventricular-pulmonary arterial coupling in a large cohort of patients with a spectrum of TR severity. METHODS: Comprehensive data were collected from patients referred for cardiac magnetic resonance from 2019 to 2024 who had TR quantification. Right ventricular-pulmonary arterial coupling was calculated by dividing the forward right ventricular stroke volume (f-RVSV) by the right ventricular end-systolic volume (ESV). The outcome of interest was the composite of all-cause death and heart failure hospitalization, under medical management. RESULTS: In the 631 patients included, median age was 66 (interquartile range [IQR], 54–75) years, median tricuspid regurgitant volume was 18 (IQR, 12–30 mL), median left ventricular ejection fraction was 53 (IQR, 41–61)%, median RV ejection fraction was 53 (IQR, 45–58)%, and median f-RVSV/ESV ratio was 0.82 (IQR, 0.58–1.11). In restricted spline curve analysis, the f-RVSV/ESV ratio cutoff associated with a hazard >1 for the composite outcome was ≤0.57. At baseline, a low f-RVSV/ESV ratio was strongly associated with subjective and objective signs of right heart failure, higher TRI-SCORE, and worse right-sided chamber remodeling (all P P P =0.004). Finally, patients with low f-RVSV/ESV displayed a worse long-term prognosis across mild, moderate, and severe TR groups ( P P P =0.018, respectively). CONCLUSIONS: In this large cohort of patients with a wide spectrum of TR severity, right ventricular-pulmonary arterial coupling assessed by cardiac magnetic resonance was strongly associated with right-sided heart failure and worse long-term prognosis, even after comprehensive adjustment.
- Open Access
- 24 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 4915
Invasive Coronary Physiology in Contemporary Practice: From Lesion Selection to Comprehensive PCI Guidance and Functional Phenotyping
Background/Objectives: Invasive coronary physiology has evolved from a tool for assessing intermediate stenoses to a comprehensive framework for guiding diagnosis and treatment across the spectrum of coronary artery disease (CAD). This review aims to provide an updated, catheterization laboratory-centered overview of contemporary invasive coronary physiology, emphasizing its role in optimizing percutaneous coronary intervention (PCI) and in evaluating patients with angina and non-obstructive coronary arteries (ANOCA/INOCA). Methods: A narrative review of contemporary evidence, including randomized trials, consensus documents, and guideline recommendations, was conducted. Key physiological indices—fractional flow reserve (FFR), non-hyperemic pressure ratios (NHPRs), coronary flow reserve (CFR), and index of microcirculatory resistance (IMR)—were examined alongside emerging tools such as longitudinal vessel analysis and the pullback pressure gradient (PPG). Applications in pre- and post-PCI assessment, physiology–imaging integration, and comprehensive functional testing in ANOCA/INOCA were evaluated. Results: Physiology-guided PCI improves clinical outcomes and resource utilization compared with angiography-guided strategies. Longitudinal vessel assessment and PPG enable characterization of focal versus diffuse CAD, improving procedural planning and prediction of post-PCI physiological results. Post-PCI physiological assessment identifies residual ischemia and guides optimization strategies. In patients without obstructive CAD, combined assessment of microvascular function and vasomotor reactivity allows identification of distinct pathophysiological endotypes, supporting mechanism-based, individualized therapy. Integration with intracoronary imaging further enhances procedural precision. Conclusions: Contemporary invasive coronary physiology provides a multidimensional approach integrating epicardial, microvascular, and vasomotor domains. This framework supports personalized decision-making, optimizes revascularization, and reduces unnecessary interventions, representing a cornerstone of modern coronary care.
- 24 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 4915
Open AccessInvasive Coronary Physiology in Contemporary Practice: From Lesion Selection to Comprehensive PCI Guidance and Functional Phenotyping
Background/Objectives: Invasive coronary physiology has evolved from a tool for assessing intermediate stenoses to a comprehensive framework for guiding diagnosis and treatment across the spectrum of coronary artery disease (CAD). This review aims to provide an updated, catheterization laboratory-centered overview of contemporary invasive coronary physiology, emphasizing its role in optimizing percutaneous coronary intervention (PCI) and in evaluating patients with angina and non-obstructive coronary arteries (ANOCA/INOCA). Methods: A narrative review of contemporary evidence, including randomized trials, consensus documents, and guideline recommendations, was conducted. Key physiological indices—fractional flow reserve (FFR), non-hyperemic pressure ratios (NHPRs), coronary flow reserve (CFR), and index of microcirculatory resistance (IMR)—were examined alongside emerging tools such as longitudinal vessel analysis and the pullback pressure gradient (PPG). Applications in pre- and post-PCI assessment, physiology–imaging integration, and comprehensive functional testing in ANOCA/INOCA were evaluated. Results: Physiology-guided PCI improves clinical outcomes and resource utilization compared with angiography-guided strategies. Longitudinal vessel assessment and PPG enable characterization of focal versus diffuse CAD, improving procedural planning and prediction of post-PCI physiological results. Post-PCI physiological assessment identifies residual ischemia and guides optimization strategies. In patients without obstructive CAD, combined assessment of microvascular function and vasomotor reactivity allows identification of distinct pathophysiological endotypes, supporting mechanism-based, individualized therapy. Integration with intracoronary imaging further enhances procedural precision. Conclusions: Contemporary invasive coronary physiology provides a multidimensional approach integrating epicardial, microvascular, and vasomotor domains. This framework supports personalized decision-making, optimizes revascularization, and reduces unnecessary interventions, representing a cornerstone of modern coronary care.
- 29 December 2025
- Published by Elsevier in Canadian Journal of Cardiology
Tricuspid Transcatheter Intervention: A Field Still Waiting for Answers
- 29 December 2025
- Published by Elsevier in Canadian Journal of Cardiology
Tricuspid Transcatheter Intervention: A Field Still Waiting for Answers
- 1 November 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (11) , e012489
Hemodynamic Right Heart Catheterization Before Transcatheter Mitral and Tricuspid Therapies
Recent findings emphasize the potential role of invasive hemodynamic assessment in guiding transcatheter mitral and tricuspid valve percutaneous interventions. Right heart catheterization-derived parameters offer insights into hemodynamic changes associated with valvular heart diseases, pulmonary hypertension phenotyping, and right ventricular to pulmonary artery coupling. This might improve prognostic stratification for candidates to transcatheter therapies. This review provides a clinical overview of available data regarding the utility of preoperative right heart catheterization-derived parameters in patients undergoing mitral and tricuspid percutaneous repair or replacement.
- 1 November 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (11) , e012489
Hemodynamic Right Heart Catheterization Before Transcatheter Mitral and Tricuspid Therapies
Recent findings emphasize the potential role of invasive hemodynamic assessment in guiding transcatheter mitral and tricuspid valve percutaneous interventions. Right heart catheterization-derived parameters offer insights into hemodynamic changes associated with valvular heart diseases, pulmonary hypertension phenotyping, and right ventricular to pulmonary artery coupling. This might improve prognostic stratification for candidates to transcatheter therapies. This review provides a clinical overview of available data regarding the utility of preoperative right heart catheterization-derived parameters in patients undergoing mitral and tricuspid percutaneous repair or replacement.
- Open Access
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e040496
Competing Risks of Cardiac and Noncardiac Mortality in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge‐to‐Edge Repair
Background: The relative impact of cardiac and noncardiac mortality in patients with secondary mitral regurgitation undergoing mitral transcatheter edge‐to‐edge repair (M‐TEER) has been poorly investigated. We aimed to assess the competing risks and independent predictors of cardiac and noncardiac mortality in a real‐world secondary mitral regurgitation population treated with M‐TEER and included in the GIOTTO (Italian Society of Interventional Cardiology [GIse] Registry Of Transcatheter Treatment of Mitral Valve Regurgitation) registry. Methods: Competing risks analysis was used to assess the cumulative incidence of cardiac and noncardiac mortality. Cox regression identified independent predictors of each outcome. Co‐primary outcomes were cardiac and noncardiac death at 2 years. Results: The analysis included 1185 consecutive patients with secondary mitral regurgitation treated with M‐TEER between January 2016 and March 2020 (median age 74 years). Two‐year cumulative incidences of cardiac and noncardiac mortality were 19% and 12%, respectively. At multivariable analysis, predictors of cardiac mortality were age (hazard ratio [HR], 1.03; P =0.002), New York Heart Association class (HR, 1.44; P =0.018), previous hospitalization for heart failure (HR, 1.67; P =0.016), hemoglobin (HR, 0.89; P =0.016), left ventricular end‐diastolic diameter (HR, 1.02; P =0.025), left ventricular ejection fraction (HR, 0.98; P =0.022), and daily furosemide dose (HR, 1.19; P =0.003). Predictors of noncardiac mortality were New York Heart Association class (HR, 1.70; P =0.03), estimated glomerular filtration rate (HR, 0.98; P =0.002), and smoking habit (HR, 1.82; P =0.009). Conclusions: Patients with secondary mitral regurgitation treated with M‐TEER show a high 2‐year incidence of both cardiac and noncardiac mortality. Understanding competing risks of mortality may improve patient selection for M‐TEER.
- 21 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (20) , e040496
Open AccessCompeting Risks of Cardiac and Noncardiac Mortality in Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge‐to‐Edge Repair
Background: The relative impact of cardiac and noncardiac mortality in patients with secondary mitral regurgitation undergoing mitral transcatheter edge‐to‐edge repair (M‐TEER) has been poorly investigated. We aimed to assess the competing risks and independent predictors of cardiac and noncardiac mortality in a real‐world secondary mitral regurgitation population treated with M‐TEER and included in the GIOTTO (Italian Society of Interventional Cardiology [GIse] Registry Of Transcatheter Treatment of Mitral Valve Regurgitation) registry. Methods: Competing risks analysis was used to assess the cumulative incidence of cardiac and noncardiac mortality. Cox regression identified independent predictors of each outcome. Co‐primary outcomes were cardiac and noncardiac death at 2 years. Results: The analysis included 1185 consecutive patients with secondary mitral regurgitation treated with M‐TEER between January 2016 and March 2020 (median age 74 years). Two‐year cumulative incidences of cardiac and noncardiac mortality were 19% and 12%, respectively. At multivariable analysis, predictors of cardiac mortality were age (hazard ratio [HR], 1.03; P =0.002), New York Heart Association class (HR, 1.44; P =0.018), previous hospitalization for heart failure (HR, 1.67; P =0.016), hemoglobin (HR, 0.89; P =0.016), left ventricular end‐diastolic diameter (HR, 1.02; P =0.025), left ventricular ejection fraction (HR, 0.98; P =0.022), and daily furosemide dose (HR, 1.19; P =0.003). Predictors of noncardiac mortality were New York Heart Association class (HR, 1.70; P =0.03), estimated glomerular filtration rate (HR, 0.98; P =0.002), and smoking habit (HR, 1.82; P =0.009). Conclusions: Patients with secondary mitral regurgitation treated with M‐TEER show a high 2‐year incidence of both cardiac and noncardiac mortality. Understanding competing risks of mortality may improve patient selection for M‐TEER.
- Open Access
- 5 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (15) , e041713
Combined Percutaneous Left Atrial Appendage Closure and Mitral Transcatheter Edge‐to‐Edge Repair: Current Evidence and Practical Considerations
Atrial fibrillation commonly coexists with severe mitral regurgitation, complicating management by necessitating long‐term anticoagulation, with its associated bleeding risk. The combined approach of percutaneous left atrial appendage closure and mitral transcatheter edge‐to‐edge repair has been proposed as a comprehensive solution, mitigating stroke risk while addressing mitral regurgitation. This approach eliminates the need for a second procedure and lifelong oral anticoagulants. Our review provides insights into the benefits and risks of combined procedures, potentially aiding clinicians in optimizing management for these patients. Long‐term follow‐up will determine whether combining these interventions improves prognosis in high‐risk patients with atrial fibrillation.
- 5 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (15) , e041713
Open AccessCombined Percutaneous Left Atrial Appendage Closure and Mitral Transcatheter Edge‐to‐Edge Repair: Current Evidence and Practical Considerations
Atrial fibrillation commonly coexists with severe mitral regurgitation, complicating management by necessitating long‐term anticoagulation, with its associated bleeding risk. The combined approach of percutaneous left atrial appendage closure and mitral transcatheter edge‐to‐edge repair has been proposed as a comprehensive solution, mitigating stroke risk while addressing mitral regurgitation. This approach eliminates the need for a second procedure and lifelong oral anticoagulants. Our review provides insights into the benefits and risks of combined procedures, potentially aiding clinicians in optimizing management for these patients. Long‐term follow‐up will determine whether combining these interventions improves prognosis in high‐risk patients with atrial fibrillation.
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (8) , e012813
Determinants of Right Heart Hemodynamic Derangement in Patients With and Without Tricuspid Regurgitation
BACKGROUND: The determinants of tricuspid regurgitation (TR) hemodynamic severity remain to be established. We explored the hemodynamic correlates of right atrial (RA) pressure and stroke volume (SV) in patients with and without TR, and assessed the reliability of the indirect Fick method in relation to TR severity. METHODS: In this observational study, right ventricular (RV) 3-dimensional echocardiography (3DE) was obtained simultaneously with direct Fick right heart catheterization. RVSV 3DE and SV RHC were combined to determine the TR regurgitant fraction (RegFr=RVSV 3DE -RVSV RHC /RVSV 3DE ). RA pressures and strain (or 3DE volumes) were combined to derive RA compliance. RESULTS: Out of 74 patients, 61% had moderate or severe TR. TR severity was associated with larger right heart chambers, lower RA compliance, higher values and lower inspiratory decrease of RA pressure, and lower cardiac index ( P r =−0.57) and with ln-transformed RA compliance strain ( r =−0.74); SV index was associated with RegFr ( r =−0.65). The effect of RegFr on V wave was mediated by ln-transformed RA compliance strain (β, 13.9 [95% CI, 7.6–20.2]). In multivariable analysis, RA V wave remained associated with 1/RA compliance strain (β, 2.1 [95% CI, 1.4–2.7]), while SV index was associated with RegFr (β, −97.6 [95% CI, −120.1 to −75.0]). The indirect Fick method overestimated cardiac index proportionally to RegFr ( P <0.01). CONCLUSIONS: SV index is related to TR severity, while the effect of TR on RA V wave is mediated by RA compliance. Respiratory-related changes in RA hemodynamics are associated with TR severity. The indirect Fick method overestimates cardiac index proportionally to TR severity.
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (8) , e012813
Open AccessDeterminants of Right Heart Hemodynamic Derangement in Patients With and Without Tricuspid Regurgitation
BACKGROUND: The determinants of tricuspid regurgitation (TR) hemodynamic severity remain to be established. We explored the hemodynamic correlates of right atrial (RA) pressure and stroke volume (SV) in patients with and without TR, and assessed the reliability of the indirect Fick method in relation to TR severity. METHODS: In this observational study, right ventricular (RV) 3-dimensional echocardiography (3DE) was obtained simultaneously with direct Fick right heart catheterization. RVSV 3DE and SV RHC were combined to determine the TR regurgitant fraction (RegFr=RVSV 3DE -RVSV RHC /RVSV 3DE ). RA pressures and strain (or 3DE volumes) were combined to derive RA compliance. RESULTS: Out of 74 patients, 61% had moderate or severe TR. TR severity was associated with larger right heart chambers, lower RA compliance, higher values and lower inspiratory decrease of RA pressure, and lower cardiac index ( P r =−0.57) and with ln-transformed RA compliance strain ( r =−0.74); SV index was associated with RegFr ( r =−0.65). The effect of RegFr on V wave was mediated by ln-transformed RA compliance strain (β, 13.9 [95% CI, 7.6–20.2]). In multivariable analysis, RA V wave remained associated with 1/RA compliance strain (β, 2.1 [95% CI, 1.4–2.7]), while SV index was associated with RegFr (β, −97.6 [95% CI, −120.1 to −75.0]). The indirect Fick method overestimated cardiac index proportionally to RegFr ( P <0.01). CONCLUSIONS: SV index is related to TR severity, while the effect of TR on RA V wave is mediated by RA compliance. Respiratory-related changes in RA hemodynamics are associated with TR severity. The indirect Fick method overestimates cardiac index proportionally to TR severity.